Prostate cancer screening becomes increasingly risky as men age, with the chance of detecting a cancer that would never harm them jumping from 16% at age 50 to 58% at age 80. A new analysis of over 400,000 men reveals that current screening practices, especially in older adults, are catching cancers that would remain silent for life, leading to unnecessary surgery, radiation, and other treatments with serious side effects.

What Is Prostate Cancer Overdiagnosis, and Why Should You Care?

Overdiagnosis sounds like a medical term, but it's actually a straightforward problem: finding a cancer through screening that would never have caused symptoms or harmed a person during their lifetime. In prostate cancer, this happens when a prostate-specific antigen (PSA) blood test detects slow-growing tumors that men would likely die with, not from. The difference matters enormously because treatment for prostate cancer, including surgery and radiation therapy, carries real risks like incontinence, erectile dysfunction, and bowel problems.

Researchers at Queen Mary University of London analyzed long-term data from the UK CAP trial, which tracked more than 400,000 men over 15 years. They compared how many prostate cancers were found through PSA screening versus how many would have actually caused problems if men hadn't been screened. The findings paint a troubling picture, especially for older men.

How Does Age Change the Risk of Overdiagnosis?

The study's most striking finding is how dramatically overdiagnosis risk climbs with age. Here's what the researchers discovered when they factored in the reality that older men are more likely to die from other causes before a slow-growing prostate cancer ever becomes a problem:

• Age 50: Men had a 16% chance their detected cancer would never have been diagnosed within 15 years without screening
• Age 59: The risk rose to 20%, meaning one in five detected cancers would have remained silent
• Age 64: The overdiagnosis rate climbed to 24%
• Age 70: About one in three cancers detected (32%) would never have caused harm
• Age 80: The risk skyrocketed to 58%, meaning more than half of detected cancers would have gone unnoticed for life

Why does age matter so much? As men get older, competing causes of death become more likely. A 75-year-old man is far more likely to die from heart disease, stroke, or other conditions than from a slow-growing prostate cancer. Yet current screening practices often continue testing men well into their 70s and 80s, catching cancers that pose minimal lifetime risk.

The overall rate of overdiagnosis across all ages was 11.7%, meaning roughly one in nine prostate cancers detected by PSA screening would have remained undiagnosed if men hadn't been screened.

How Are Current Screening Policies Contributing to the Problem?

U.S. guidelines from the American Cancer Society and U.S. Preventive Services Task Force (USPSTF) have recommended against routine PSA screening in men aged 70 and older since 2012. However, screening still happens regularly outside these guidelines, often triggered by unrelated health concerns like erectile dysfunction or blood in the urine.

In the United Kingdom, where this study was conducted, a "PSA tests on demand" policy has created high rates of opportunistic screening in older men. This means men can request PSA tests through primary care without a specific medical reason, and doctors often comply. The result: older men who are at highest risk of overdiagnosis are being screened most aggressively.

"These findings suggest the need for more targeted, age-informed PSA testing or prostate cancer screening policies, including reexamining PSA testing policies in settings where they have led to high rates of opportunistic screening in older men, like the UK. The current 'PSA tests on demand' healthcare policy has led to high rates of opportunistic PSA testing in older men, who are at high risk of harms from overdiagnosis," stated Dr. Adam Brentnall, a Reader in Biostatistics at Queen Mary's Wolfson Institute of Population Health and lead author of the study.

Dr. Adam Brentnall, Reader in Biostatistics, Queen Mary University of London

Dr. Brentnall emphasized that the harms of overdiagnosis extend beyond unnecessary worry. Men whose cancers would never have caused problems undergo surgery, radiation, and other treatments that carry significant side effects and can substantially reduce quality of life.

What Do Recent Screening Policy Changes Tell Us?

A separate analysis published in the World Journal of Urology examined how the 2012 and 2018 USPSTF recommendations affected prostate cancer diagnosis and mortality across the United States. The findings reveal the real-world consequences of shifting screening practices.

When the 2012 recommendation against routine PSA screening was released, overall prostate cancer incidence dropped by 20.6% almost immediately. However, this came with a troubling trade-off: cases of metastatic prostate cancer, the most dangerous form, rose by 9.3%. In other words, while fewer men were being diagnosed with early-stage disease, more men were presenting with advanced cancer that had already spread.

The 2018 update to the USPSTF guidelines, which recommended shared decision-making for men aged 55 to 69, partially reversed these trends. Mortality rates, which had slowed between 2012 and 2017, began falling more rapidly again after 2018. The data suggests that completely eliminating screening isn't the answer, but neither is screening everyone.

Black men and residents of the Southern United States experienced the most pronounced shifts in prostate cancer epidemiology, highlighting significant disparities in how screening policy changes affect different populations.

Steps to Make Smarter Screening Decisions

Based on current evidence, here's what men and their doctors should consider when deciding about prostate cancer screening:

• Age-Appropriate Screening: Men in their 50s and early 60s benefit most from PSA screening, as overdiagnosis rates are lowest in this group. Men over 70 should generally avoid routine screening unless they have specific risk factors or symptoms.
• Shared Decision-Making: Rather than automatic screening, men aged 55 to 69 should discuss the benefits and risks with their doctor, considering family history, race, and personal health status before deciding to get tested.
• Avoid Opportunistic Testing: Men should resist requesting PSA tests for unrelated health concerns like erectile dysfunction or urinary symptoms. These conditions don't indicate a need for prostate cancer screening and can lead to unnecessary testing in older adults.
• Ask About Alternatives: Newer techniques like magnetic resonance imaging (MRI) targeted biopsy can better distinguish slow-growing cancers from aggressive ones, reducing unnecessary biopsies and treatment. Ask your doctor if these options are available.

What's Next for Prostate Cancer Screening?

The researchers note that their analysis has limitations. The UK CAP trial conducted screening between 2001 and 2007, before MRI-guided biopsy and other modern techniques became standard. These newer methods are expected to reduce overdiagnosis by better identifying which cancers actually need treatment.

Ongoing trials, including TRANSFORM and IMProVE, are currently testing contemporary screening protocols to provide updated evidence on overdiagnosis rates with today's technology. These studies may help refine screening recommendations further.

In the meantime, the message is clear: one-size-fits-all prostate cancer screening, especially in older men, causes more harm than good. Moving toward age-informed, risk-adapted screening with shared decision-making offers the best path forward to catch dangerous cancers while protecting men from the harms of overdiagnosis.